Sjögren's syndrome overview

Jump to navigation Jump to search

Sjögren's syndrome Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Sjögren's syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Sjögren's syndrome overview On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Sjögren's syndrome overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Sjögren's syndrome overview

CDC on Sjögren's syndrome overview

Sjögren's syndrome overview in the news

Blogs on Sjögren's syndrome overview

Directions to Hospitals Treating Sjögren's syndrome

Risk calculators and risk factors for Sjögren's syndrome overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Farima Kahe M.D. [2]

Overview

In 1892, Johann von Mikulicz-Radecki was to first to describe a patient with enlargement of the parotid and lacrimal glands associated with a round-cell infiltrate and acinar atrophy. In 1933, Henrik Sjögren was the first to describe 19 females with clinical and pathological manifestations of the Sjögren's syndrome. American-European Consensus Group(AECG) and American College of Rheumatology (ACR) established the criteria for Sjögren’s syndrome in 2002 and 2012 according to clinical findings. Common causes of Sjögren's syndrome include viral infection such as Epstein-Barr virus (EBV), Coxsackie virus, Hepatitis C virus, Cytomegalovirus (CMV), Human herpesvirus 6 (HHV-6), Retroviruses, and genetic factors. The incidence of Sjögren's syndrome is approximately 4 per 100,000 individuals worldwide. The prevalence of Sjögren's syndrome is approximately 43 per 100,000 individuals worldwide. Female are more commonly affected by Sjögren's syndrome than male. The majority of Sjögren's syndrome cases are reported in China, Japan, and California. Common risk factors in the development of Sjögren's syndrome include family history of autoimmune diseases, serological markers such as low complement levels and cryoglobulinemia and parotid gland enlargement. The symptoms of Sjögren's syndrome usually develop in the 4th and 5th decade of life, and start with symptoms such as ocular and oral dryness. Common complications of Sjögren's syndrome include blurred vision and corneal damage, optic neuritis, and lymphoma. Prognosis is generally good and presence of low complement level is associated with a particularly poor prognosis among patients with Sjögren's syndrome. The most common symptoms of Sjögren's syndrome include ocular and oral symptoms. Patients with Sjögren's syndrome may have a positive history of rheumatoid arthritis (RA), systemic lupus erythematous (SLE) and non-Hodgkin B-cell lymphoma. Physical examination of patients with is usually remarkable for dryness of all mucous membranes such as mouth, eyes, lips, anal and rectal. Laboratory findings consistent with the diagnosis of Sjögren's syndrome include elevated erythrocyte sedimentation rate (ESR), cytopenia, the presence of anti-SSA/Ro, anti-SSB/La. Findings on an ultrasound suggestive of Sjögren's syndrome are hypoechoic and inhomogeneous salivary glands, parenchymal inhomogeneity in the submandibular glands and focal or diffuse hypoechoic or anechoic foci in glands. Parotid gland CT scan may be helpful in the diagnosis of Sjögren's syndrome and finding include abnormal diffuse fat tissue deposition and diffuse punctate calcification. The most commonly used tests for dry eyes of Sjögren's syndrome include Schirmer's test, ocular surface staining and tear break-up time. Pharmacologic medical therapies for dry eye, dry mouth, and other sicca symptoms of Sjögren's syndrome are pilocarpine, cevimeline and artificial tears. The mainstay of treatment for Sjögren's syndrome is medical therapy. Surgery is usually reserved for patients with occlusion of the lacrimal puncta, salivary gland malignancy and recurrent parotitis refractory to medical management.

Historical Perspective

In 1892, Johann von Mikulicz-Radecki was to first to describe a patient with with enlargement of the parotid and lacrimal glands associated with a round-cell infiltrate and acinar atrophy. In 1933, Henrik Sjögren was the first to describe 19 females with clinical and pathological manifestations of the Sjögren's syndrome.

Classification

American-European Consensus Group(AECG) and American College of Rheumatology (ACR) established the criteria for Sjögren’s syndrome in 2002 and 2012 according to clinical findings.

Pathophysiology

Sjögren's syndrome (SS) is a chronic auto-immune disorder that can affect several organ systems. It is classified into a "primary" form that is a separate entity from other well-defined autoimmune disorders and a "secondary" form that is associated with other well-defined autoimmune conditions, such as SLErheumatoid arthritisprogressive systemic sclerosis, and primary biliary cirrhosis. These forms are different in their serologic and histopathologic findings as well as their genetic components. Both genetic and immune factors contribute to the pathogenesis of the disease. In the most common presentation of the disease, lymphocytes infiltrate the lacrimal and salivary glands and impair their function, hence causing the main characteristic symptoms- dry mouth (keratoconjunctivitis sicca) and eyes (xerostomia). CD4+ T-cells are predominant in mild and moderate salivary gland infiltrations, while B cells play the major role in severe lesions. The disease may also manifest itself with dryness of skin and other mucosal surfaces or even cause systemic extraglandular disturbances such as arthritisvasculitis and renal, pulmonary, hematopoietic and neurologic involvement. In general, a combination of lymphocytic infiltration, B lymphocyte hyperreactivity, production of certain autoantibodiesgenes mostly involved in the production of MHC molecules and certain viral infectionsare all linked to the pathogenesis of SS.

Causes

Common causes of Sjögren's syndrome include viral infection such as Epstein-Barr virus (EBV), Coxsackie virus, Hepatitis C virus, Cytomegalovirus (CMV), Human herpesvirus 6 (HHV-6), Retroviruses and genetic factors.

Differentiating Sjögren's syndrome overview from Other Diseases

Epidemiology and Demographics

The incidence of Sjögren's syndrome is approximately 4 per 100,000 individuals worldwide. The prevalence of Sjögren's syndrome is approximately 43 per 100,000 individuals worldwide. Female are more commonly affected by Sjögren's syndrome than male. The majority of Sjögren's syndrome cases are reported in China, Japan, and California.

Risk Factors

Common risk factors in the development of Sjögren's syndrome include family history of autoimmune diseases, serological markers such as low complement levels and cryoglobulinaemia and parotid gland enlargement.

Screening

There is insufficient evidence to recommend routine screening for Sjögren's syndrome.

Natural History, Complications, and Prognosis

Natural History

The symptoms of Sjögren's syndrome usually develop in the 4th and 5th decade of life, and start with symptoms such as ocular and oral dryness.

Complications

Common complications of Sjögren's syndrome include blurred vision and corneal damage, optic neuritis and lymphoma.

Prognosis

Prognosis is generally good and presence of low complement level is associated with a particularly poor prognosis among patients with Sjögren's syndrome.

Diagnosis

Diagnostic Criteria

History and Symptoms

The most common symptoms of Sjögren's syndrome include ocular and oral symptoms. Patients with Sjögren's syndrome may have a positive history of rheumatoid arthritis (RA), systemic lupus erythematous (SLE) and non-Hodgkin B-cell lymphoma.

Physical Examination

Physical examination of patients with is usually remarkable for dryness of all mucous membranes such as mouth, eyes, lips, anal and rectal.

Laboratory Findings

Laboratory findings consistent with the diagnosis of Sjögren's syndrome include Elevated erythrocyte sedimentation rate (ESR), cytopenia, presence of anti-SSA/Ro, anti-SSB/La.

Imaging Findings

Findings on an ultrasound suggestive of Sjögren's syndrome are hypoechoic and inhomogeneous salivary glands, parenchymal inhomogeneity in the submandibular glands and focal or diffuse hypoechoic or anechoic foci in glands. Parotid gland CT scan may be helpful in the diagnosis of Sjögren's syndrome and finding include abnormal diffuse fat tissue deposition and diffuse punctate calcification.

Other Diagnostic Studies

The most commonly used tests for dry eyes of Sjögren's syndrome include Schirmer test, ocular surface staining and tear break-up time.

Treatment

Medical Therapy

Pharmacologic medical therapies for dry eye, dry mouth, and other sicca symptom of Sjögren's syndrome are Pilocarpine, Cevimeline and artifical tears.

Surgery

The mainstay of treatment for Sjögren's syndrome is medical therapy. Surgery is usually reserved for patients with occlusion of the lacrimal puncta, salivary gland malignancy and recurrent parotitis refractory to medical management.

Prevention

References